Detalhe da pesquisa
1.
6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial.
Lancet
; 393(10191): 2591-2598, 2019 06 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-31178155
2.
6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial.
Lancet Oncol
; 14(8): 741-8, 2013 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-23764181
3.
Cemiplimab for Locally Advanced and Metastatic Cutaneous Squamous-Cell Carcinomas: Real-Life Experience from the French CAREPI Study Group.
Cancers (Basel)
; 13(14)2021 Jul 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34298764
4.
Decision of adjuvant chemotherapy in intermediate risk luminal breast cancer patients: A prospective multicenter trial assessing the clinical and psychological impact of EndoPredict® (EpClin) use (UCBG 2-14).
Breast
; 49: 132-140, 2020 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-31790959
5.
Results of PONDx, a prospective multicenter study of the Oncotype DX® breast cancer assay: Real-life utilization and decision impact in French clinical practice.
Breast
; 44: 39-45, 2019 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-30634106